With over 20 years of experience in clinical research, Brandy Lind is a seasoned leader in project management.  As Vice President of Global Project Management at Rho, Ms. Lind has played a pivotal role in driving the successful execution of complex, multi-phase clinical trials and development programs across a variety of therapeutic areas.  Specifically, she has specialized in asthma, allergic diseases, transplantation, and dermatology programs.

Ms. Lind’s career began with the NIAID/NIH-funded Inner City Asthma Consortium (ICAC), where she supported groundbreaking clinical trials, including studies on anti-IgE therapy and exhaled nitric oxide tests—research that helped shape national asthma guidelines. She later served as Program Director for the Statistical and Data Coordinating Center of the Immune Tolerance Network (ITN), overseeing more than 30 studies focused on allergy, immunology, and transplantation.

In recent years, Ms. Lind has expanded her expertise into dermatology, managing a comprehensive global dermatology development program that included 14 Phase I-III studies, culminating in a successful New Drug Application (NDA) submission.  As part of this program, she also supported the client through several successful regulatory inspections.

Ms. Lind has provided expert oversight for a wide range of clinical trials, demonstrating her skill in managing complex portfolios, ensuring adherence to enrollment goals, study timelines, regulatory standards, and budgets.  Her ability to build and lead high-performing project teams has been a hallmark of her career. Ms. Lind is known for her meticulous attention to detail, her capacity to drive results in challenging environments, and her unwavering commitment to quality and compliance. Whether managing a single study or a global portfolio, she ensures that every aspect of the trial is executed with precision, ensuring optimal outcomes for both patients and sponsors.